Biggest Side Effects of Gabapentin
The most significant adverse effects of gabapentin are dizziness (28% in postherpetic neuralgia), somnolence (19-21%), and peripheral edema (8%), with serious concerns for falls/fractures, respiratory depression when combined with opioids, and dose-dependent neurological impairment. 1
Most Common Adverse Effects
The FDA-approved labeling clearly identifies the primary side effects based on controlled trials:
Neurological Effects (Most Frequent)
- Dizziness: Occurs in 17-28% of patients depending on indication, compared to 7-8% with placebo 1
- Somnolence/Sedation: Affects 19-21% of patients (vs 5-9% placebo) 1
- Ataxia: Present in 13% of epilepsy patients and 3% of postherpetic neuralgia patients 1
- Fatigue: Reported in 11% of patients 1
These neurological effects show a clear dose-response relationship, with somnolence and ataxia increasing at doses ≥1800 mg daily 1.
Other Common Effects
- Peripheral edema: 8% (vs 2% placebo) 1
- Weight gain: 2-3% of patients 1
- Gastrointestinal: Nausea (4%), dizziness, dry mouth (5%), constipation (4%) 1
Serious Adverse Effects Requiring Vigilance
Falls and Fractures
A dose-dependent relationship exists between gabapentin and falls/fractures, with risk elevated even at doses as low as 100 mg/day. 2 In a large veteran cohort, the incidence was 1.81 per 100 person-years in exposed patients versus 1.34 in unexposed (RR 1.35) 3. Risk escalates dramatically at higher doses:
Altered Mental Status
Incidence of 1.08 per 100 person-years (RR 1.12 vs unexposed), with highest risk at doses 600-2399 mg/day 3. This includes confusion, cognitive impairment, and encephalopathy 4.
Respiratory Depression
Critical concern when combined with opioids or other CNS depressants. Concurrent opioid use increases risk substantially:
Visual Disturbances
- Diplopia: 6% in epilepsy patients, 1% in postherpetic neuralgia 1
- Blurred vision (amblyopia): 3-4% 1
- Emerging signals for more serious ocular effects including potential retinal effects 6
Serious But Rare Complications
The FDA labeling highlights critical warnings for:
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) 1
- Anaphylaxis and angioedema 1
- Suicidal behavior and ideation 1
- Withdrawal-precipitated seizures (if discontinued abruptly) 1
- Sudden unexplained death in epilepsy patients 1
Atypical Effects
Recent literature identifies additional concerns:
- Myoclonus and dyskinesia 4
- Pediatric aggression and hostility (8% in children 3-12 years) 1, 4
- Anorgasmia and sexual dysfunction 1, 4
- Rhabdomyolysis (rare) 1
Discontinuation Rates
16% of patients discontinued gabapentin due to adverse effects in postherpetic neuralgia trials (vs 9% placebo), with dizziness, somnolence, and nausea being the most common reasons. 1 In epilepsy trials, 7% discontinued, primarily due to somnolence (1.2%), ataxia (0.8%), and fatigue (0.6%) 1.
High-Risk Populations
Adverse effects are particularly concerning in:
- Hemodialysis patients: Event rates of 37.8 per 100 patient-years for altered mental status, with risk at doses as low as 100 mg/day 2
- Patients with substance use history: 2.4-fold increased risk of substance misuse 5
- Elderly patients: Increased incidence of adverse reactions with age 1
- Patients on concurrent CNS depressants: Multiplicative risk with opioids, benzodiazepines, Z-drugs 5
Clinical Pitfalls
Common prescribing error: Using doses lower than evidence-based effective doses (1200-3600 mg/day) 7, yet even these lower doses carry significant adverse effect risk 2, 3. The therapeutic window is narrow, with substantial benefit occurring in only 32-38% of patients at effective doses 8, while over half experience no worthwhile pain relief but remain exposed to adverse effects.
Critical monitoring points: Screen for falls risk, cognitive changes, respiratory depression (especially with opioid co-prescription), and visual disturbances. Consider dose reduction or discontinuation if adverse effects emerge, particularly in vulnerable populations.